Health profiles and quality of life of 518 survivors of thyroid cancer

Head and Neck

Volumn 25, Issue 5, 2003, Pages 349-356

  Schultz, Pamela N ^a   Stava, Charles ^a   Vassilopoulou Sellin, Rena ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Late effects; Survivorship; Thyroid cancer

Indexed keywords

ADULT; ARTHRITIS; ARTICLE; CANCER SURVIVAL; DEMOGRAPHY; FAMILY; FEMALE; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MIGRAINE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; THYROID CANCER; WELLBEING; WORK;

ADOLESCENT; ADULT; AGED; EMPLOYMENT; FAMILY RELATIONS; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; THYROID NEOPLASMS;

EID: 0344511761     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10217     Document Type: Article

References (26)

1. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714-720.
2. Vassilopoulou-Sellin R. Management of papillary thyroid cancer. Oncology 1995;9:145-151.
3. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocrine Pract 2000;6:469-476.
4. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001;86:1447-1463.
5. Kebebew E, Clark OH. Differentiated thyroid cancer: "complete" rational approach. World J Surg 2000;24:942-951.
6. Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Control 2000;7:229-239.
7. Rossi RL, Majlis S, Ross RM. Thyroid cancer. Surg Clin North Am 2000;80:571-580.
8. Schlumberger MJ. Diagnostic follow-up of well-differentiated thyroid carcinoma: historical perspective and current status. J Endocrinol Invest 1999;22(11 Suppl):3-7.
9. Meadows AT, Hobbie WL. The medical consequences of cure. Cancer 1986;15(suppl 2):524-528.
10. Ried H, Zietz H, Jaffe N. Late effects of cancer treatment in children. Pediatr Dent 1995;65(suppl 3):770-775.
11. Schultz PN, Beck MI, Stava C, Vassilopoulou-Sellin R. Health effects and quality of life in 5143 adult long term cancer survivors. Paper presented at the American Association of Clinical Oncology Annual Meeting, Orlando, FL. May 18-21, 2002.
12. Schultz PN, Beck ML, Stava C, Vassilopoulou-Sellin R. Cancer survivors: work related issues. American Association of Occupational Health Nursing Journal 2002;50:5, in press.
13. Dow KH, Ferrell BR, Anello C. Balancing demands of cancer surveillance among survivors of thyroid cancer. Cancer Practice 1997;5:289-295.
14. National Prevalence. United States Department of Health and Human Services: Center for Disease Control and Prevention, National Center for Health Statistics, 1999. National Vital Statistics Report.
15. Peres MF, Sanchez del Rio M, Seabra ML, et al. Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 2001;71:747-751.
16. Fanciullacci M, Alessandri M, Del Rosso A. Dopamine involvement in the migraine attack. Funct Neurol 2000;3:171-181.
17. Hartman N, Voron SC, Hershman JM. Resolution of migraine following bromocriptine treatment of a prolactinoma (pituitary microadenoma). Headache 1995;35:430-431.
18. Papakostas Y, Daras M, Markianos M, Stefanis C. Increased prolactin response to thyrotropin releasing hormone during migraine attacks. J Neurol Neurosurg Psychiatry 1987;50:927-928.
19. Murialdo G, Masturzo P, Ferrari ML, et al. Thyroidstimulating hormone and prolactin responses to thyrotropin-releasing hormone in common migraine. Cephalalgia 1987;7:267-272.
20. Dugbartey AT. Neurocognitive aspects of hypothyroidism. Arch Intern Med 1998;158:1413-1418.
21. Haggerty JJ, Evans DL, Prange AJ. Organic brain syndrome associated with marginal hypothyroidism. Am J Psychiatry 1986;143:785-786.
22. Nemeroff CB, Loosen PT. Handbook of clinical psychoneuroendocrinology. New York: Guilford Press, 1987.
23. Pollock MA, Sturrock A, Marshall K, et al. Thyroxine treatment in patients with symptoms of hypothyroidism but thyroid function tests within the reference range: randomised double blind placebo controlled crossover trial. Br Med J 2001;323:891-895.
24. Walsh JP, Stuckey BG. What is the optimal treatment for hypothyroidism? Med J Aust 2001;174:141-143.
25. Zabora J, Brintzenhofeszoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology 2001;10:19-28.
26. Wiersinga WM. Thyroid hormone replacement therapy. Horm Res 2001;56(suppl S1):74-81.